Showing results (21-30 of 51) with videos related to
Sort By:
Pageof 6
Current HIV Research|March 30, 2004
Molecular mechanisms and biological significance of CTL avidityJames T Snyder, Martha A Alexander-Miller, Jay A Berzofskyl, et al.Virology|December 1, 2007
Enhanced cell surface expression, immunogenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed by a recombinant MVALinda S Wyatt, Igor M Belyakov, Patricia L Earl, et al.Virology|September 17, 2008
Generation of functionally active HIV-1 specific CD8+ CTL in intestinal mucosa following mucosal, systemic or mixed prime-boost immunizationIgor M Belyakov, Jeffrey D Ahlers, Gary J Nabel, et al.Journal of Immunology (Baltimore, Md. : 1950)|October 24, 2006
Enhancement of CD8+ T cell immunity in the lung by CpG oligodeoxynucleotides increases protective efficacy of a modified vaccinia Ankara vaccine against lethal poxvirus infection even in a CD4-deficient hostIgor M Belyakov, Dmitry Isakov, Qing Zhu, et al.International Immunology|March 23, 2007
Avidity of CD8 T cells sharpens immunodominanceAmiran H Dzutsev, Igor M Belyakov, Dmitry V Isakov, et al.Journal of Virology|May 30, 2006
The NS2 protein of human respiratory syncytial virus suppresses the cytotoxic T-cell response as a consequence of suppressing the type I interferon responseAlexander Kotelkin, Igor M Belyakov, Lijuan Yang, et al.The Journal of Clinical Investigation|April 2, 2004
Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cellsIgor M Belyakov, Scott A Hammond, Jeffrey D Ahlers, et al.Blood|August 1, 2002
DNA vaccines encoding human immunodeficiency virus-1 glycoprotein 120 fusions with proinflammatory chemoattractants induce systemic and mucosal immune responsesArya Biragyn, Igor M Belyakov, Yen-Hung Chow, et al.The Journal of Clinical Investigation|August 18, 2004
Progress on new vaccine strategies against chronic viral infectionsJay A Berzofsky, Jeffrey D Ahlers, John Janik, et al.The Journal of Clinical Investigation|January 27, 2010
Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in miceQing Zhu, Colt Egelston, Susan Gagnon, et al.Pageof 6